Clinical trial · Interventional
Reduction of Cancer Related Fatigue in Patients During TKI Therapy
Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Cancer Patients During Tyrosine Kinase Inhibitor Therapy
NCT01645150CI-TRIAL-00021441RECAPcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this pilot study is to determine the effects of a 12-week resistance training program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor (TKI) therapy. It is hypothesized that incidence and severity of cancer related fatigue can be reduced by exercise training in this population which leads to an improved treatment completion rate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| All Tumor Entities Treated With TKI Therapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Progressive strength training | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Strength training group
- description
- 12 weeks of progressive strength training
- interventionNames
- Behavioral: Progressive strength training
- type
- NO_INTERVENTION
- label
- Control group
- description
- No intervention
Primary outcomes (1)
- measure
- Change in cancer related fatigue
- timeFrame
- From baseline to the 6th and 12th week of training.
- description
- Assessed via the Multidimensional Fatigue Inventory (MFI).
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female cancer patients * Prior to tyrosine kinase inhibitor therapy (any substance, any line) * Age: at least 18 yrs * Body mass index (BMI): at least 18 kg/m2 * ECOG performance status: at most 2 * Must be able to meet the requirements of the study protocol Exclusion Criteria: * Acute infectious diseases * No ambulatory ability * Severe neurological disorders * Severe cardiovascular diseases * Severe pulmonary insufficiency * Severe renal insufficiency * Other current tumor diseases * Conditions rendering compliance impossible * Participation in regular strength training
References
Publications (1)
- DERIVEDRosenberger F, Wiskemann J, Vallet S, Haag GM, Schembri E, Jager D, Grullich C. Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial. Support Care Cancer. 2017 Dec;25(12):3655-3664. doi: 10.1007/s00520-017-3788-3. Epub 2017 Jun 30. PMID 28667563